Head-To-Head Review: NeurAxis (NASDAQ:NRXS) and Guided Therapeutics (OTCMKTS:GTHP)

Risk & Volatility

NeurAxis has a beta of 4.2, suggesting that its stock price is 320% more volatile than the S&P 500. Comparatively, Guided Therapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500.

Profitability

This table compares NeurAxis and Guided Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
Guided Therapeutics	N/A	N/A	-151.93%

Earnings & Valuation

This table compares NeurAxis and Guided Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$2.46 million	6.75	-$14.63 million	($1.84)	-1.26
Guided Therapeutics	$100,000.00	65.49	-$3.49 million	($0.03)	-3.33

Guided Therapeutics has lower revenue, but higher earnings than NeurAxis. Guided Therapeutics is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

11.8% of NeurAxis shares are owned by institutional investors. Comparatively, 9.7% of Guided Therapeutics shares are owned by institutional investors. 15.2% of NeurAxis shares are owned by company insiders. Comparatively, 66.8% of Guided Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Guided Therapeutics beats NeurAxis on 6 of the 10 factors compared between the two stocks.

About NeurAxis

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

About Guided Therapeutics

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.